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Abstract
Introduction: HIV prevalence among state prison inmates in the United States is more than five times higher than among
nonincarcerated persons, but HIV transmission within U.S. prisons is sparsely documented. We investigated 88 HIV
seroconversions reported from 1988–2005 among male Georgia prison inmates.
Methods: We analyzed medical and administrative data to describe seroconverters’ HIV testing histories and performed a
case-crossover analysis of their risks before and after HIV diagnosis. We sequenced the gag, env, and pol genes of
seroconverters’ HIV strains to identify genetically-related HIV transmission clusters and antiretroviral resistance. We
combined risk, genetic, and administrative data to describe prison HIV transmission networks.
Results: Forty-one (47%) seroconverters were diagnosed with HIV from July 2003–June 2005 when voluntary annual testing
was offered. Seroconverters were less likely to report sex (OR [odds ratio]=0.02, 95% CI [confidence interval]: 0–0.10) and
tattooing (OR=0.03, 95% CI: ,0.01–0.20) in prison after their HIV diagnosis than before. Of 67 seroconverters’ specimens
tested, 33 (49%) fell into one of 10 genetically-related clusters; of these, 25 (76%) reported sex in prison before their HIV
diagnosis. The HIV strains of 8 (61%) of 13 antiretroviral-naı ¨ve and 21 (40%) of 52 antiretroviral-treated seroconverters were
antiretroviral-resistant.
Discussion: Half of all HIV seroconversions were identified when routine voluntary testing was offered, and seroconverters
reduced their risks following their diagnosis. Most genetically-related seroconverters reported sex in prison, suggesting HIV
transmission through sexual networks. Resistance testing before initiating antiretroviral therapy is important for newly-
diagnosed inmates.
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Introduction
The estimated prevalence of HIV infection in the United States is
more than five times higher among state prison inmates (1.9%) than
for the general population (0.37%) [1,2]. Although most inmates
with HIV are infected before they enter prison, HIV risk behaviors,
and occasionally HIV infection, during incarceration have been
reported [3–7]. However, sparse information is available on HIV
transmission within large state prison systems in general and on
inmates’ risk modification after HIV diagnosis, HIV transmission
networks, or antiretroviral drug resistance in particular.
During 2004–2006, the Centers for Disease Control and
Prevention (CDC), the Georgia Division of Public Health
(GDPH), and the Georgia Department of Corrections (GDC)
conducted an epidemiologic investigation of all 88 known HIV
seroconversions identified among male GDC prison inmates since
mandatory HIV screening for all new inmates was initiated in
1988. No seroconversions were reported among female inmates.
In a previous case-control study among GDC male inmates, we
found that sex in prison, tattooing in prison, black race, and a
body mass index of 25.4 kg/m2 or less were significantly
associated with HIV seroconversion [7].
In this paper, we follow up on our previous report by combining
data from medical and administrative records, behavioral risk
interviews, and genetic analysis of seroconverters’ HIV strains to
describe HIV transmission networks within the GDC prison
system. We use interview data to describe self-reported risk
modification among seroconverters after their HIV diagnosis.
Because tattooing—which was associated with HIV seroconver-
sion in the initial case-control study—is an unproven mode of HIV
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5416transmission, we re-interviewed seroconverters who initially
reported tattooing as their only potential risk for HIV infection.
Methods
GDC intake and HIV testing processes
In Georgia, inmates charged with a felony offense are housed in
local or county jails while awaiting sentencing. Most jails do not
offer HIV testing to inmates. After sentencing, inmates are
transferred to a GDC reception center for security classification
and an entry medical evaluation and then to one of 73 GDC
facilities. In July 1988, GDC initiated mandatory HIV screening of
all inmates during their entry medical evaluation. Voluntary annual
HIV testing was offered to inmates from July 2003–June 2005.
Inmates are also tested upon their request, if clinically indicated,
upon a court order, or following an incident involving their
exposure to blood or body fluids; they are not tested before release.
Definitions
Duration of incarceration was defined as the time an inmate
remained in continuous correctional custody from his jail entry date
through his release from prison, death, or the last date of data
collection, whichever occurred earlier; seroconversion as at least 1
negative HIV test result after the start of incarceration followed by a
confirmed positive HIV test result during the same incarceration;
movement as an inmate’s transfer between correctional facilities
(jails, county prisons, state prisons, private prisons, transitional
centers); and a facility where HIV infection definitely occurred as
oneinwhichaseroconverterhad anegativeHIVtestresultfollowed
by a confirmed positive result during the same stay at that facility.
Procedures
Recruitment. We recruited male seroconverters aged 18
years or older from 31 GDC facilities where seroconverters resided
from February 2005–March 2005. All participants provided
written informed consent for interviews and blood specimen
collection. CDC determined that these activities, as a public health
response to a request to investigate HIV transmission in a state
prison system, did not require institutional review board approval
under human-subjects protection guidelines, and the state’s
Institutional Review Board of record concurred.
Seroconverters’Characteristics. Wereviewed GDC medical
and administrative data to describe seroconverters’ demographic
characteristics, number of previous prison incarcerations, offense
type, and year and duration of current incarceration.
HIV Infection During Incarceration. To confirm that the
reported seroconversions occurred during incarceration, we
reviewed GDC medical and administrative data to calculate, for
each seroconverter, the number of negative HIV test results and the
time from the start of incarceration to the first negative result and to
the positive result. We also examined seroconverters’ movement
histories to identify the facility where the infection occurred.
HIV Risk Behaviors. We used Questionnaire Development
System v2.1 software (Nova Research, Bethesda, MD) to develop
and administer audio computer-assisted self-interviews (ACASI) to
collect data on seroconverters’ risk behaviors before and during
incarceration. We asked 74 seroconverters incarcerated at the time
of the investigation to participate in these interviews and obtained
written informed consent from all of them. Two seroconverters
had died and we did not attempt to contact the 12 seroconverters
who had been released. To determine if knowledge of HIV
infection was associated with a reduction in risk behaviors, we
performed a matched-pairs case-crossover analysis of inmates’ self-
reported risk behaviors before and after HIV diagnosis. We used
SAS v9.1 software (SAS Institute, Cary, NC) to calculate exact
odds ratios (ORs) and 95% confidence intervals (CIs) and Fisher’s
exact test to determine whether differences in risks before and after
HIV diagnosis were significant (p values,0.05).
For 12 seroconverters who reported in ACASI that tattooing was
their only potential risk for HIV infection during incarceration, we
conducted follow-up face-to-face structured interviews to elicit
previously unreported risks. We asked for the names of sex, IDU, or
tattooing contacts and offered HIV testing to these contacts. We did
not conduct contact-tracing activities for seroconverters who
reported an established risk for HIV transmission.
HIV Transmission Networks. To identify genetically-
related HIV strains, we collected plasma specimens from
seroconverters who participated in ACASI and from contacts
named by 2 or more seroconverters in follow-up interviews. We
amplified the p17 gag gene (396 nucleotides) and a partial fragment
of the gp41 env gene (360 nucleotides) of the HIV genome with
nested polymerase chain reaction (PCR) procedures and
sequenced them. We analyzed sequence data and constructed a
neighbor-joining phylogenetic tree, using the general time
reversible model of evolution, with the Phylogenetic Analysis
Using Parsimony (PAUP) v.4.b10 program (Sinauer Associates,
Inc., Sunderland, MA). The B.82CAN sequence (early, 1982
subtype B Canadian HIV strain) served as an outgroup sequence.
We assessed support for internal nodes with the PAUP
bootstrapping procedure and depicted internal nodes with
bootstrap support of more than 85% in a phylogenetic tree.
We assigned seroconverters with genetically-related HIV strains
to clusters and analyzed the combined cluster, inter-facility
movement, and risk data of seroconverters and their named
contacts to describe HIV transmission networks by the facility
where transmission occurred and the possible mode of transmis-
sion. For the largest cluster, we created network diagrams with
InFlow v3.0 software (Orgnet.com, Cleveland, OH) and connect-
ed each seroconverter in this cluster to all jails and GDC prisons in
which he resided during his current incarceration. For each facility
where a seroconverter in this cluster resided, we determined his
HIV infection status while in that facility as either HIV-negative,
unknown HIV status, new HIV diagnosis, or established HIV
diagnosis. We eliminated all facilities linked to only one
seroconverter to create a network of core GDC facilities, and
assigned likely modes of HIV transmission on the basis of
seroconverters’ self-reported risk behaviors.
Drug-resistant Virus Transmission. To identify antiretro-
viral drug-resistance mutations and their transmission patterns, we
used standard genotyping procedures on specimens collected from 67
seroconverters to sequence the protease and reverse transcriptase
genes of the pol region (approximately 1,930 nucleotides) of their HIV
strains. Additionally, we performed sensitive PCR-based assays for
four major drug-resistant mutations (L90M in protease, and K70R,
K103N, M184V in reverse transcriptase) on specimens collected
from 13 antiretroviral-naı ¨ve (untreated) seroconverters and from two
antiretroviral-treated seroconverters whose HIV strains did not show
antiretroviral-resistance with standard sequencing methods [8]. We
compared drug-resistant virus transmission among antiretroviral-
treated seroconverters versus antiretroviral-naı ¨ve seroconverters, and
among seroconverters with genetically-related HIV strains versus
those with unrelated strains.
Results
Seroconverters’ Characteristics
The median age of seroconverters was 24 years (range: 15–57
years) at the start of incarceration and 32 years (range: 21–58
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(33%) white; 39 (44%) had been previously incarcerated in the
Georgia state prison system a median of two times (range: 1–6
previous incarcerations); 76 (86%) had committed a violent
offense, of whom 26 (34%) had committed a sexual offense
(Table 1). Forty-five (51%) seroconverters entered prison during
1992–1998, and 30 (34%) were serving life sentences (Table 1).
Seroconverters had spent a median of 124 days (range: 4–2437
days) in jail and a median of 7 years (range: 1–20 years) in prison
before being diagnosed with HIV.
HIV Infection During Incarceration
All 88 known seroconverters were diagnosed with HIV from
September 1992–February 2005; 41 (47%) from July 2003–
February 2005, when GDC offered voluntary annual HIV testing
(Figure 1). Seroconverters had a median of one negative HIV test
result during incarceration (range: 1–7 negative tests); their first
negative result was a median of 214 days (range: 7–4576 days)
after the start of incarceration. The median duration from start of
incarceration to HIV diagnosis was 8 years (range: 1–21 years). Of
47 seroconverters with a single negative HIV test result during
incarceration, 26 (55%) were tested more than180 days after the
start of incarceration, 15 (32%) 42–180 days after, and 6 (13%) less
than 42 days after; 3 of these 6 reported having sex in prison
before their HIV diagnosis and a fourth reported sex and IDU.
We identified the GDC facility where HIV infection occurred for
36 (41%) seroconverters (Table 1).
HIV Risk Behaviors
Of 74 seroconverters approached about participating in
ACASI, 69 (93%) agreed to participate; of these, 49 (71%)
reported sex, 4 (6%) reported IDU, and 36 (41%) reported
tattooing in prison before their HIV diagnosis. In the case-
crossover analysis (n=66; three records had missing data and were
excluded), we found that seroconverters were less likely to report
sex (7 [11%] versus 49 [74%]) or tattooing (6 [9%] versus 36
[55%]) after their HIV diagnosis than before.
We re-interviewed 10 of the 12 seroconverters who originally
reported tattooing as their only potential risk for HIV infection (1
refused; 1 was on parole and unreachable); 5 reported having sex
with other male inmates during their incarceration and 5 denied
having any other potential HIV risk. The 10 re-interviewed
seroconverters named a total of 18 sex, IDU, or tattooing inmate
contacts of whom 5 were known to be HIV-infected (including two
seroconverters) and 2 could not be located; of the 11 remaining
contacts who were offered HIV testing, 9 tested HIV-negative and
2 refused.
HIV Transmission Networks
Of 74 incarcerated seroconverters who were approached for
blood specimens, 69 (93%) agreed to provide them; of these, two
had unsuccessful blood draws. Genetic analysis of combined p17
gag and partial gp41 env sequences of 67 seroconverters’ specimens
demonstrated that 33 (49%) were associated in 10 distinct
bootstrap-supported clusters (A–J) of 2–9 seroconverters each
(Figure 2). These relationships were confirmed in further genetic
analysis of pol sequences (n=65, two specimens were refractory to
amplification). Of the clustered seroconverters, 22 (67%) (includ-
ing all seroconverters in clusters A, B, E, F, G, I, and J) had
overlapping stays in the same prison with at least 1 other member
of their respective cluster (Figure 2); 26 (79%) reported having sex
(of whom 2 also reported IDU), 4 (12%) reported tattooing only,
and 3 (9%) reported no risk behaviors.
In cluster G, the single largest cluster (n=9), all 4 seroconverters
who reported having sex in prison before their HIV diagnosis
named the same inmate as their sex contact; this inmate was
infected with HIV before entering prison in 1994 and is therefore
considered a possible index case. These four seroconverters, and
four more in cluster G who reported tattooing as their only
potential risk for HIV during incarceration, had overlapping
prison stays with the possible index case; he reported tattooing as
his only risk behavior while in prison ( Figure 2). A network
diagram represents facility links for all nine members of cluster G
and the possible index case (Figure 3).
Table 1. Incarceration-related Characteristics of 88 Male
Inmates (Seroconverters*) in Whom HIV Infection Was
Diagnosed During Their Incarceration, Georgia State Prison
System, United States, 1988–2005.
Characteristics Seroconverters
n=88 %
Facility of infection
{
Definite facility identified 36 41
Probable facility identified 24 27
Unknown facility of infection 28 32
Incarceration
Previously incarcerated in Georgia prison system 39 44
Median # of previous incarcerations (range) 2 (1–6)
Current incarceration: primary offense
Violent offense
{ 76 86
Sexual offense 26 30
Nonviolent offense
1 12 14
Drug-related offense 2 2
Current incarceration start year
1978–1984 6 7
1985–1991 22 25
1992–1998 45 51
1999–2003 14 16
Median duration of current sentence (range)
I 17 (2–57)
#5 years 8 9
6–10 years 16 18
11–20 years 27 31
.20 years 37 42
Life sentence 30 34
*A seroconverter is an inmate with $1 negative HIV test result followed by a
confirmed positive HIV test result during his current incarceration.
{A definite facility of infection is one in which a seroconverter had a negative
HIV test result followed by a confirmed positive result during the same stay at
that facility; a probable facility of infection is one of two possible facilities
where a seroconverter may have become infected based on his HIV testing
history.
{Violent offenses include aggravated assault, armed robbery, attempted armed
robbery, kidnapping, murder, robbery, vehicular homicide, voluntary
manslaughter, and the sexual offenses of aggravated child molestation,
aggravated sodomy, child molestation, rape, and statutory rape.
1Nonviolent offenses include attempted burglary, burglary, conspiracy, motor
vehicle theft, and selling or dealing of narcotics.
IPrison release dates for inmates eligible for parole correspond to their
tentative parole month and year; actual prison release dates are used for
former inmates who had been released, had died, or were on parole as of
January 31, 2007; inmates serving a life sentence were assigned a sentence
duration of 50 years.
doi:10.1371/journal.pone.0005416.t001
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Of 67 seroconverters whose blood samples were analyzed for
antiretroviral drug resistance, 54 (81%) had received antiretroviral
drug treatment and 13 (20%) were antiretroviral-naive. Twenty-
nine (43%) seroconverters, including 21 who were treated and 8
who were antiretroviral-naı ¨ve, were infected with HIV strains
resistant to one or more of the three classes of antiretrovirals
including nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), and protease
inhibitors (PIs). Of 21 treated seroconverters with antiretroviral-
resistant HIV strains, 16 had single-class resistance (NRTI=10,
NNRTI=6), 4 had dual-class resistance (NRTI and NNRTI), and
1 had triple-class resistance (NRTI, NNRTI, and PI). Of 13
antiretroviral-naı ¨ve seroconverters, 8 (62%) had single-class
resistance (RTI=4, NNRTI=3, PI=1). We found similar
mutations in samples from both antiretroviral-naı ¨ve and treated
seroconverters in clusters B, H, and J (Figure 2).
Discussion
We found that 80% of seroconverters who were interviewed
reported sex or IDU in prison before their HIV diagnosis and we
identified 10 genetically-related clusters; two-thirds of seroconver-
ters in these clusters had overlapping stays in the same prison with
Figure 1. Year of HIV Diagnosis for 88 Male Inmates (Seroconverters) Who Became Infected with HIV During Incarceration, Georgia
State Prison System, United States, 1988–2005.
doi:10.1371/journal.pone.0005416.g001
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antiretroviral-treated and antiretroviral-naı ¨ve seroconverters were
infected with drug-resistant HIV strains.
Our findings highlight the importance of timely diagnosis and
appropriate treatment of HIV-infected inmates. The time between
HIV infection and diagnosis may have been shortened if routine
voluntary testing was available for more than two of the 18 years
since GDC first started testing inmates for HIV (half of all known
seroconverters were diagnosed during the 2-year period when
voluntary annual testing was offered to inmates). Frequent testing
would also have made it easier to more accurately estimate the
approximate period between infection and HIV diagnosis, and
Figure 2. Genetic Analysis of Combined p17 and gp41 Sequences of HIV Strains from 67 Seroconverters and One Trace Contact,
Georgia State Prison system, United States, 1988–2005.
doi:10.1371/journal.pone.0005416.g002
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Investigation of HIV Transmission Among 88 Inmates, Georgia State Prison system, United States, 1988–2005.
doi:10.1371/journal.pone.0005416.g003
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pre-incarceration HIV acquisition.
The significant reduction in sex and tattooing among infected
inmates following their HIV diagnosis is consistent with reports of
reduced risk behaviors among nonincarcerated people after
learning they are HIV-infected [9]. Most contacts named in
follow-up interviews were reached and tested for HIV, demon-
strating the utility of partner notification and contact-tracing
activities in correctional settings.
Although HIV testing and risk data for seroconverters suggest
that most were infected while incarcerated in GDC facilities, some
may have been infected before incarceration or during initial jail
stays before their transfer to a GDC prison. In particular, six
seroconverters who reported unprotected sex with multiple female
partners in the 6 months before incarceration and who had a
single negative HIV test result within 42 days of being incarcerated
may have had insufficient HIV antibodies to test positive at that
time. However, three of the six reported having sex during
incarceration before their HIV diagnosis. Furthermore, a quarter
of all seroconverters traveled from prison to jail and back during
their incarceration for varying lengths of time, and some of them
may have become infected during these jail stays. Recall bias
remains an important limitation in eliciting reports of risk
behaviors in this population.
We previously reported that nine percent of all known HIV-
infected male GDC inmates became infected in GDC facilities [7].
However, the actual percentage is likely to be higher because
GDC offered voluntary annual HIV testing for only 2 years and
does not test inmates prior to release. A comprehensive strategy to
test inmates for HIV on entry, periodically during incarceration,
and before release, as is recommended by CDC, would enable
correctional systems to identify newly infected inmates and provide
them with treatment and prevention services in a timely manner,
as well as provide more accurate data for HIV incidence estimates.
The observed genetic clustering, the limited number of viral
strains in circulation, and reports of sex among seroconverters with
genetically-related HIV strains suggests that HIV was transmitted
largely through sexual networks. By correlating administrative,
risk, HIV testing, and contact-tracing data, we identified a sexual
network for the largest genetic cluster; overlapping prison stays
among seroconverters in other clusters suggest that other sexual
networks existed. IDU did not appear to play a major role in HIV
transmission, although inmates may have under-reported this risk
behavior. Because only half of the seroconverters who initially
reported tattooing as their only possible risk for HIV acquisition
subsequently reported having had sex, we were unable to
categorically rule out tattooing as a potential route of HIV
transmission. However, while HIV can theoretically be transmit-
ted via tattooing with non-sterile tattooing equipment, there is no
documented case of HIV transmission via tattooing to date. The
large proportion of inmates who reported sex and tattooing in
prison indicates ACASI is a suitable method for eliciting sensitive
information in correctional settings; however, all risk behaviors of
interest are prohibited in GDC prisons and are thus likely to have
been under-reported.
Drug-resistant HIV strains were found among both antiretro-
viral-naı ¨ve and antiretroviral-treated seroconverters. The 61%
prevalence of such strains among antiretroviral-naı ¨ve seroconver-
ters was substantially higher than that reported in other
antiretroviral-naı ¨ve populations [10]. Moreover, five treated
seroconverters were infected with HIV strains resistant to two or
more classes of antiretrovirals. These findings suggest that
complying with existing recommendations for antiretroviral
drug-resistance testing before initiating a treatment regimen and
then testing inmates periodically during their antiretroviral
treatment are especially important in a prison setting. Ongoing
counseling to encourage inmates to initiate and continue
antiretroviral therapy when indicated may optimize treatment
response, reduce antiretroviral resistance, and reduce HIV
transmission [11].
HIV prevention education for incoming inmates and reinforce-
ment of HIV prevention messages for all inmates are essential to
reducing HIV risk among prisoners. We reiterate the importance
of evaluating HIV prevention interventions, such as condom
distribution, in correctional settings [7,12]. Moreover, HIV
prevention counseling for HIV-infected inmates and a system
that ensures their uninterrupted medical care upon release should
be public health priorities [7,13]. Finally, correctional agencies
should partner with public health agencies to assess and improve
existing HIV prevention and treatment programs for all inmates.
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